|
Here's an article on cancer vaccinations - colon cancer by Mike. [ed] >>>
I posted this article for you because it indicates that the future of advanced medicine is moving toward educating the immune system.
Here we find scientists experimenting with educating the immune system through vaccinations. A vaccination provides the immune system with education on a particular target, in this case colon cancer. The scientists found antibodies that recognized cancer cells and cloned them into a vaccine. The vaccine stimulated T-Cells to produce TNF-alpha which is a turmor destroying cytokine.
What is interesting here is transfer factors are within the T-Cell family and TNF-alpha was the cytokine that Dr. See's study found that our transfer factors increased its levels by 2,000%.
Where the conventional medical and pharmaceutical industry is headed through educating the immune system, we are already there to an extent! Our scientists in conjunction with scientists throughout the world are moving forward every year in targeting the immune system. We need to capture the reality of what we have in our hands! Don't look back years from now and realize that you missed one of the, potentially, greatest health trends of the past two centuries. Manipulating, educating and targeting the immune system is the future of conventional medicine.
This will be the greatest breakthrough ever for medicine. No more side effects! No more chemo and radiation! We are in front of the wave. I realize it is not easy to build a MLM business but it is doable. Give it your best shot! Let me know how we can assist you beyond what we are doing now. Mike
>>>>>>>>>
Nov. 16, 2006 -- An experimental colorectal cancer vaccine designed to enlist the immune system in killing tumor cells is showing promise in an early clinical trial.
British researchers developed the vaccine from antibodies cloned from a patient with advanced colorectal cancer who survived many years longer than expected.
When given to 67 colorectal cancer patients (average age 66) the vaccine stimulated immune responses in 70%, researchers say.
The findings are published in the Nov. 15 issue of the journal Clinical Cancer Research.
"This is the first vaccine shown to stimulate TNF-alpha -- an immune-system protein that is very effective at killing cancer cells," says immunologist Lindy Durrant, PhD, who developed the vaccine.
Once one of the most promising fields in cancer research, vaccines designed to treat patients with existing cancers have been slow to emerge.
Despite several decades of study, none has been proven to prolong the lives of cancer patients.
Durrant, who is a professor at the University of Nottingham in England, tells WebMD that she has been working on the colorectal cancer vaccine for about 10 years.
The vaccine is designed to work by stimulating the production of immune cells called T-cells, which in turn produce immune system proteins called cytokines that destroy cancer cells.
Because cancer cells are so slow to grow, the body does not usually recognize them as a threat and does not mount an immune response to them.
"We have been working on ways to re-educate the immune system or essentially trick it into recognizing cancer cells early on," Durrant tells WebMD.
Her vaccine was derived from a colorectal cancer patient who survived for seven years after cancer had spread to his liver.
"This is very unusual as most patients die within one year of getting liver metastases," Durrant says. "I thought if this antibody helped this patient, if we could clone it, it might help others."
The cancer patients included in the trial were immunized both before and after undergoing surgery to remove their primary tumors.
Of the patients treated repeatedly with the experimental vaccine, just over two-thirds appeared to exhibit measurable immune responses.
Nineteen of the 67 patients died during two years of follow-up, but the trial was not designed to study the effect of the vaccine on survival.
Durrant says she hopes to find funding for a larger, longer study with survival as an end point.
Ertl says the development of cancer-treatment vaccines has gotten ahead of the science, and that is why the clinical trials have generally been disappointing.
"We need to know more about the immune system and how it is regulated before we can devise vaccine treatments that work," she says. "We have learned a lot over the past few years. That knowledge should be used to try and make existing vaccines better."
|
|